Oral Lefamulin vs Moxifloxacin for Early Clinical Response Among Adults With Community-Acquired Bacterial Pneumonia: The LEAP 2 Randomized Clinical Trial

IMPORTANCE: New antibacterials are needed to treat community-acquired bacterial pneumonia (CABP) because of growing antibacterial resistance and safety concerns with standard care. OBJECTIVE: To evaluate the efficacy and adverse events of a 5-day oral lefamulin regimen in patients with CABP. DESIGN,...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:JAMA
Autors principals: Alexander, Elizabeth, Goldberg, Lisa, Das, Anita F., Moran, Gregory J., Sandrock, Christian, Gasink, Leanne B., Spera, Patricia, Sweeney, Carolyn, Paukner, Susanne, Wicha, Wolfgang W., Gelone, Steven P., Schranz, Jennifer
Format: Artigo
Idioma:Inglês
Publicat: American Medical Association 2019
Matèries:
Original Investigation
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6865224/
https://ncbi.nlm.nih.gov/pubmed/31560372
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jama.2019.15468
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars